"たけだP" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonDoes Takeda Pharmaceutical (TSE:4502) Still Offer Value After Strong Multi‑Year Share Price Gains...
Does Takeda Pharmaceutical (TSE:4502) Still Offer Value After Strong Multi‑Year Share Price Gains? simplywall.st
Takeda trims sales force to navigate patent loss - Новости GxP
Takeda trims sales force to navigate patent loss Новости GxP
Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Confer...
Takeda patent expiry primes Korea P-CAB shake-up, puts Daewon at risk - CHOSUNBIZ - Chosunbiz
Takeda patent expiry primes Korea P-CAB shake-up, puts Daewon at risk - CHOSUNBIZ Chosunbiz
Protagonist-Takeda, Novartis post phase III wins - BioWorld News
Protagonist-Takeda, Novartis post phase III wins BioWorld News
Paddington Life Sciences Symposium celebrates the power of collaboration in life sciences - Imper...
Paddington Life Sciences Symposium celebrates the power of collaboration in life sciences Imperial College Healthcare NHS Trust
Takeda: Lack Of Realistic Upside In Japanese Pharma (NYSE:TAK) - Seeking Alpha
Takeda: Lack Of Realistic Upside In Japanese Pharma (NYSE:TAK) Seeking Alpha
Takeda takes Blue Bay — Quotes from the Amateur Asia-Pacific - The IX Sports
Takeda takes Blue Bay — Quotes from the Amateur Asia-Pacific The IX Sports
Enantioselective α‐Aminoxylation of Ketones Catalyzed by a Chiral Brønsted Acid - Wiley
Enantioselective α‐Aminoxylation of Ketones Catalyzed by a Chiral Brønsted Acid Wiley
Takeda’s TAK-861 Shows Promise in Improving Wakefulness in Phase 1 Trial Among Healthy Men - Neur...
Takeda’s TAK-861 Shows Promise in Improving Wakefulness in Phase 1 Trial Among Healthy Men NeurologyLive
ASCO25: Takeda, Protagonist make strong case for phlebotomy successor in polycythemia vera - Firs...
ASCO25: Takeda, Protagonist make strong case for phlebotomy successor in polycythemia vera FirstWord Pharma
Takeda's Poseida partnership starts to pay off with promising hemophilia A gene therapy data - Fi...
Takeda's Poseida partnership starts to pay off with promising hemophilia A gene therapy data Fierce Biotech
Christophe Weber, President and CEO - Takeda Pharmaceuticals
Christophe Weber, President and CEO Takeda Pharmaceuticals
Iclusig comes too late to rescue Takeda | ApexOnco - Clinical Trials news and analysis - Oncology...
Iclusig comes too late to rescue Takeda | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Takeda G protein–coupled receptor 5 (TGR5): an attractive therapeutic target for aging-related ca...
Orexin-Targeting Agent TAK-861 Meets All End Points in Phase 3 FirstLight and RadiantLight Studie...
Orexin-Targeting Agent TAK-861 Meets All End Points in Phase 3 FirstLight and RadiantLight Studies NeurologyLive
Takeda-backed Poseida puts off-the-shelf CAR-T in its basket, places autologous therapy back on t...
Takeda-backed Poseida puts off-the-shelf CAR-T in its basket, places autologous therapy back on the shelf Fierce Biotech
Stock Information & Shareholder Returns - Takeda Pharmaceuticals
Stock Information & Shareholder Returns Takeda Pharmaceuticals
Soticlestat Shows Mixed Results in Phase 3 Studies of Dravet and Lennox-Gastaut Syndrome - Neurol...
Soticlestat Shows Mixed Results in Phase 3 Studies of Dravet and Lennox-Gastaut Syndrome NeurologyLive
Takeda’s narcolepsy blockbuster hopeful secures double phase 3 wins, teeing up FDA filing - Fierc...
Takeda’s narcolepsy blockbuster hopeful secures double phase 3 wins, teeing up FDA filing Fierce Biotech
Korean pharmas race for generic P-CAB market amid Takeda's uncertain future for Vocinti - koreabi...
Korean pharmas race for generic P-CAB market amid Takeda's uncertain future for Vocinti koreabiomed.com
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, ...
Scoop: San Diego Biotech Partners with Takeda, Lands $1.2B Milestone Deal - Business San Diego
Scoop: San Diego Biotech Partners with Takeda, Lands $1.2B Milestone Deal Business San Diego
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide ...
Takeda’s market exit and return of vonoprazan raise stakes in Korea’s drug pricing battle - korea...
Takeda’s market exit and return of vonoprazan raise stakes in Korea’s drug pricing battle koreabiomed.com
Neurocrine-Takeda med reduces depression severity in phase 2, though analysts ask for more data d...
Neurocrine-Takeda med reduces depression severity in phase 2, though analysts ask for more data detail Fierce Biotech
A Look at Innovent Biologics (SEHK:1801) Valuation After Strategic Global Partnership With Takeda...
A Look at Innovent Biologics (SEHK:1801) Valuation After Strategic Global Partnership With Takeda Yahoo Finance
Takeda taps Julie Kim as next CEO, 1st Korean American to lead global pharma company - koreabiome...
Takeda taps Julie Kim as next CEO, 1st Korean American to lead global pharma company koreabiomed.com
Takeda PH promotes equitable access to medicines at SEA Summit - Philippine News Agency
Takeda PH promotes equitable access to medicines at SEA Summit Philippine News Agency
Takeda Pushes One Narcolepsy Program into Phase III, Discontinues Another - BioSpace
Takeda Pushes One Narcolepsy Program into Phase III, Discontinues Another BioSpace
Neurocrine’s Takeda-Partnered Drug Candidate Aces Phase II Depression Study - BioSpace
Neurocrine’s Takeda-Partnered Drug Candidate Aces Phase II Depression Study BioSpace
Takeda powers toward pivotal trials after phase 2b narcolepsy win but pauses multi-indication dre...
Takeda powers toward pivotal trials after phase 2b narcolepsy win but pauses multi-indication dream Fierce Biotech
Anion‐Responsive Colorimetric and Fluorometric Red‐Shift in Triarylborane Derivatives: Dual Role ...
$11.4B Deal Ambition Fails to Boost Stock Price - 36 Kr
Jeil Pharm's Jaqbo falls short in Korea’s booming P-CAB market with weak 1st-month sales - koreab...
Jeil Pharm's Jaqbo falls short in Korea’s booming P-CAB market with weak 1st-month sales koreabiomed.com
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlest...
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat Stock Titan
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris - The Motley Fool
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris The Motley Fool
Takeda Korea names Peter Trang as head of business operations - koreabiomed.com
Takeda Korea names Peter Trang as head of business operations koreabiomed.com
‘Cooking is a beautiful thing’: A chef's journey from Hope to Estonia - Fraser Valley Current
‘Cooking is a beautiful thing’: A chef's journey from Hope to Estonia Fraser Valley Current
Pioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologi...
Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severe...
Torrent Pharma Licenses Vonoprazan GERD Drug from Takeda - Rediff MoneyWiz
Torrent Pharma Licenses Vonoprazan GERD Drug from Takeda Rediff MoneyWiz
Torrent Pharma in pact with Takeda to commercialize acid reflux drug - Mint
Torrent Pharma in pact with Takeda to commercialize acid reflux drug Mint
Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from A...
Torrent Pharma, Takeda to commercialise GI drug in India - The Times of India
Torrent Pharma, Takeda to commercialise GI drug in India The Times of India
Fabrication of Ultra-Thin Printed Organic TFT CMOS Logic Circuits Optimized for Low-Voltage Weara...
Loss and Gain: Surviving the 2011 Tohoku Tsunami | Disaster Archipelago: Japan - commons.trincoll...
Loss and Gain: Surviving the 2011 Tohoku Tsunami | Disaster Archipelago: Japan commons.trincoll.edu
Takeda Pharmaceutical names Serina Fischer as head of India operations - ETHRWorld.com
Takeda Pharmaceutical names Serina Fischer as head of India operations ETHRWorld.com
Takeda Pharmaceutical Co Ltd (TAK) Stock Price, Quote, News & History - Benzinga
Takeda Pharmaceutical Co Ltd (TAK) Stock Price, Quote, News & History Benzinga
Zydus ties with Takeda to sell GERD drug - Mint
Should I buy Takeda Pharmaceutical Co. (TAK) - Zacks Investment Research
Should I buy Takeda Pharmaceutical Co. (TAK) Zacks Investment Research
Mankind Pharma signs agreement with Takeda to commercialize Vonoprazan in India - Indian Pharma Post
Mankind Pharma signs agreement with Takeda to commercialize Vonoprazan in India Indian Pharma Post
Mankind Pharma inks pact with Takeda to commercialise Vonoprazan in India - ET HealthWorld
Mankind Pharma inks pact with Takeda to commercialise Vonoprazan in India ET HealthWorld
Lupin partners with Takeda to commercialise Vonoprazan - Express Pharma
Lupin partners with Takeda to commercialise Vonoprazan Express Pharma
Cipla signs agreement with Takeda to commercialise Vonoprazan - Express Pharma
Cipla signs agreement with Takeda to commercialise Vonoprazan Express Pharma
Alkem signs non-exclusive patent license agreement with Takeda to commercialise Vonoprazan in Ind...
Alkem signs non-exclusive patent license agreement with Takeda to commercialise Vonoprazan in India Express Pharma
Mankind Pharma inks pact with Takeda to commercialise acidity drug in India - Business Standard
Mankind Pharma inks pact with Takeda to commercialise acidity drug in India Business Standard
Zydus inks licensing pact with Takeda to sell GERD drug - Zee Business
Zydus inks licensing pact with Takeda to sell GERD drug Zee Business
Lupin joins hand with Takeda to Launch Vonoprazan Tablets in India - Business Standard
Lupin joins hand with Takeda to Launch Vonoprazan Tablets in India Business Standard
TAKECAB® Now Available for the Treatment of Acid-related Diseases in Japan - otsuka.co.jp
TAKECAB® Now Available for the Treatment of Acid-related Diseases in Japan otsuka.co.jp